Display Settings:

Format

Send to:

Choose Destination
    Cell Stem Cell. 2009 Aug 7;5(2):168-77.

    DLL4 blockade inhibits tumor growth and reduces tumor-initiating cell frequency.

    Source

    OncoMed Pharmaceuticals Inc., Redwood City, CA 94063, USA. timothy.hoey@oncomed.com

    Abstract

    Previous studies have shown that blocking DLL4 signaling reduced tumor growth by disrupting productive angiogenesis. We developed selective anti-human and anti-mouse DLL4 antibodies to dissect the mechanisms involved by analyzing the contributions of selectively targeting DLL4 in the tumor or in the host vasculature and stroma in xenograft models derived from primary human tumors. We found that each antibody inhibited tumor growth and that the combination of the two antibodies was more effective than either alone. Treatment with anti-human DLL4 inhibited the expression of Notch target genes and reduced proliferation of tumor cells. Furthermore, we found that specifically inhibiting human DLL4 in the tumor, either alone or in combination with the chemotherapeutic agent irinotecan, reduced cancer stem cell frequency, as shown by flow cytometric and in vivo tumorigenicity studies.

    PMID:
    19664991
    [PubMed - indexed for MEDLINE]

      Supplemental Content

      Icon for Elsevier Science Icon for F1000

      Save items

      loading

      Recent activity

      Your browsing activity is empty.

      Activity recording is turned off.

      Turn recording back on

      See more...
      Write to the Help Desk